个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Cheng, A-L.[1] * ; Yen, C-J.[2] ; Cheng, Q.[3] ; Lin, C-C.[1] ; Huang, P.[4] ; Li, D.[5] ; Li, Y.[5] ; Wang, J.[6] ; Sun, M.[7] ; Wen, Q.[7] ; Gu, S.[8] ; Du, X.[9] ; Qian, J.[10] ; Liu, C.[11] ; Zhang, F.[12] ; Dai, C.[13] ; Li, G.[14] ; Ding, X.[15] ; Liu, J.[16] ; Chen, X-P.[3] ;
单位： [1]NTUH Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan [2]NCKUH Natl Cheng Kung Univ Hosp, Div Hematooncol, Tainan, Taiwan [3]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan, Peoples R China [4]Harbin Med Univ, Gastroenterol Dept 1, Canc Hosp, Harbin, Peoples R China [5]Chongqing Univ, Dept Hepatobiliary & Pancreat Oncol, Phase I Ward, Canc Hosp, Chongqing, Peoples R China [6]Zhengzhou Univ, Gastroenterol Dept Ward 1, Henan Canc Hosp, Affiliated Canc Hosp, Zhengzhou, Peoples R China [7]Jinan Cent Hosp, Dept Oncol, Phase I Ward, Jinan, Peoples R China [8]Hunan Canc Hosp, Intervent Radiol Dept, Changsha, Peoples R China [9]Mianyang Cent Hosp, Dept Oncol, Mianyang, Peoples R China [10]Bengbu Med Coll, Intervent Dept, Affiliated Hosp 1, Bengbu, Peoples R China [11]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Biliopancreat Surg, Guangzhou, Peoples R China [12]Hubei Canc Hosp, Hepatobiliary Pancreatol, Nanjing, Peoples R China [13]China Med Univ, Hepatobiliary Splen Surg, Shengjing Hosp, Shenyang, Peoples R China [14]Beijing Tsinghua Changgung Hosp, Radiotherapy Dept, Beijing, Peoples R China [15]Ningxia Med Univ, Dept Infect Dis, Gen Hosp, Yinchuan, Peoples R China [16]Fujian Canc Hosp, Hepatobiliary Surg, Fuzhou, Peoples R China
出处：
DOI： 10.1016/j.annonc.2023.09.2969
ISSN：
基金：
Abbisko Therapeutics Co., Ltd.
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者单位： [1]NTUH Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
推荐引用方式(GB/T 7714)：
Cheng A-L.,Yen C-J.,Cheng Q.,et al.First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression[J].ANNALS OF ONCOLOGY.2023,34:S617-S617.doi:10.1016/j.annonc.2023.09.2969.
APA：
Cheng, A-L.,Yen, C-J.,Cheng, Q.,Lin, C-C.,Huang, P....&Chen, X-P..(2023).First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression.ANNALS OF ONCOLOGY,34,
MLA：
Cheng, A-L.,et al."First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression".ANNALS OF ONCOLOGY 34.(2023):S617-S617

资源点击量：426 今日访问量：2 总访问量：410 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）